Analysts Offer Insights on Healthcare Companies: Cormedix (CRMD), Cutera (CUTR) and Universal Health (UHS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cormedix (CRMD – Research Report), Cutera (CUTR – Research Report) and Universal Health (UHS – Research Report).

Cormedix (CRMD)

Needham analyst Serge Belanger reiterated a Buy rating on Cormedix today and set a price target of $13.00. The company’s shares closed last Monday at $5.15.

According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.3% and a 43.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, KalVista Pharmaceuticals, and Arcutis Biotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cormedix with a $14.50 average price target, a 179.4% upside from current levels. In a report issued on May 1, JMP Securities also reiterated a Buy rating on the stock with a $16.00 price target.

See the top stocks recommended by analysts >>

Cutera (CUTR)

Stephens analyst George Sellers reiterated a Buy rating on Cutera today and set a price target of $42.00. The company’s shares closed last Monday at $16.17, close to its 52-week low of $13.21.

According to TipRanks.com, Sellers is a 2-star analyst with an average return of 0.8% and a 61.1% success rate. Sellers covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Treace Medical Concepts, and Anika Therapeutics.

Cutera has an analyst consensus of Hold, with a price target consensus of $28.00.

Universal Health (UHS)

In a report released today, Jamie Perse from Goldman Sachs maintained a Sell rating on Universal Health, with a price target of $139.00. The company’s shares closed last Monday at $138.06.

According to TipRanks.com, Perse is ranked #3823 out of 8379 analysts.

Currently, the analyst consensus on Universal Health is a Hold with an average price target of $148.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CRMD:

• CorMedix Inc. Announces Resubmission of New Drug Application for DefenCath
• CorMedix Inc. To Report First Quarter 2023 Financial Results and Provide a Corporate Update on May 15, 2023
• CorMedix Inc. to Participate in Two Upcoming Investor Conferences
• CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
• CorMedix announces notice of allowance for U.S. patent covering DefenCath